Gemcitabine and vinorelbine chemotherapy for refractory or relapsing aggressive non‐Hodgkin lymphoma

Sivam, Vanessa; Cook, Lucy; Hughes, Gail; Karadimitris, Anasatasios; Marks, Alexandra J.; Matthey, Francis; Naresh, Kikkeri N.; Szydlo, Richard; Yarranton, Helen; Kanfer, Edward; Macdonald, Donald

doi:10.1002/hon.2011

Cited by 4 publications

(9 citation statements)

References 11 publications

(10 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Regarding LDH: 40% of patients had elevated LDH levels, while 60% of patients had normal LDH levels. This was in agreement with many previous studies as LDH was elevated in 36.5% in (Sivam et al, 2012) [5] study, 37% of cases in (Gopal et al, 2010) study, and 44% in [6,7] studied. However, in [12], 73.3% of patients had elevated LDH.…”

Section: Discussionsupporting

confidence: 93%

“…This agreed with (Gopal et al, 2010) [11] study, on patients with relapsed/refractory lymphoma, as the median age in the study group was 58 years (range: 19 -79) and females represents 41% of cases. Also, in [5] study the median age of the studied patients was 67 years (range 19-87) also there was a male predominance, male/female: 13/9.…”

Section: Discussionmentioning

confidence: 69%

“…With this approach, a significant proportion of cases will achieve a cure. Nevertheless, there remains a group of patients with ongoing disease specifically those who fail salvage therapy, and /or elderly patients ineligible for ASCT [5]. Such patients may yet respond to and benefit from further chemotherapy.…”

Section: Standard Therapy For Aggressive Non-hodgkin Lymphoma Is Now Well Establishedmentioning

confidence: 99%

See 2 more Smart Citations

Gemcitabine Plus Vinorelbine for Refractory or Relapsing Non-Hodgkin Lymphoma: Response Rate and Survival

Elbary

Saed

Hussein

et al. 2021

JAMMR

View full text Add to dashboard Cite

Background: Two chemotherapeutic agents, vinorelbine and gemcitabine, have shown encouraging early results in the treatment of heavily pre-treated relapsed or refractory lymphoma when used as single agents, with responses of between 20 and 47%. This work aimed to evaluate the role of gemcitabine and vinorelbine in the treatment of relapsed and /or refractory aggressive Non-Hodgkin Lymphoma (NHL) as regard response rate, survival analysis. Methods: This prospective study was conducted on 20 patients who had relapsed and /or refractory NHL and treated with a minimum follow of 6 months. All patients were subjected to full clinical examination, laboratory and radiological study. Vinorelbine, Gemcitabine, dexamethasone, filgrastim (VGF) was administrated, On days 1 and 8, patients received vinorelbine 25 mg/m2, Gemcitabine 1000 mg/m2 and Dexamethasone 16mg/m2 I.V, On day 9, they received peg-filgrastim 6 mg subcutaneously, Patients received 4 cycles of VGF, Assessment was performed after 4th cycle of treatment and according to response during follow up period, the patient received 2 more cycles with minimum follow up 6 months and/or PET-CT was done in all patients to evaluate response rate. Results: Regarding status; 60 % of patients were relapsed and 40% of them were refractory. Regarding line therapy: all patients were treated with 1st line protocol of Rituxan/Rituximab-Cyclophosphamide-Hydroxydaunorubicin-Oncovin-Prednisone regimen (R-CHOP), and 4 of them had been treated with 2nd line chemotherapy of Ifosfamide, Cisplatin or Carboplatin, and Etoposide (ICE). So 80% of patients received VGF chemotherapy as 2nd line, while 20% of them received it as the 3rd line. And there was no statistical difference between relapsed and refractory groups regarding lines of VGF chemotherapy. Regarding the toxicity of VGF (toxicity criteria as defined by Chesson and WHO); 50% of patients complicated with grade III anaemia, 50% of patients complicated with grade III neutropenia, 60% of patients complicated with grade III thrombocytopenia, 20% of patients complicated with grade II GIT upset, 40% of patients complicated grade II thrombophlebitis and 40% of patients complicated with grade II neurotoxicity. Conclusions: VGF shows substantial activity in relapsed or refractory aggressive NHL. The regimen is generally well-tolerated, but haematological toxicity is common.

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Discussionmentioning

confidence: 69%

Section: Standard Therapy For Aggressive Non-hodgkin Lymphoma Is Now Well Establishedmentioning

confidence: 99%

See 1 more Smart Citation

Gemcitabine Plus Vinorelbine for Refractory or Relapsing Non-Hodgkin Lymphoma: Response Rate and Survival

Elbary

Saed

Hussein

et al. 2021

JAMMR

View full text Add to dashboard Cite

show abstract

“…1,[4][5][6][7] The single drug regimen, such as liposomal DOX, 1,8 gemcitabine (GEM), [9][10][11][12][13][14] and liposomal VCR, 1,15 has been proven to treat B-cell lymphoma in clinical trials. Based on their (DOX, GEM and VCR [DGV]) different mechanisms of action, the combination chemotherapies of DGV are effective and well tolerated in relapse and refractory NHL.…”

Section: Introductionmentioning

confidence: 99%

Lymph cancer chemotherapy: delivery of doxorubicin-gemcitabine prodrug and vincristine by nanostructured lipid carriers

Ni¹,

Qiu²,

Zhang³

et al. 2017

IJN

View full text Add to dashboard Cite

Purpose Radiation and chemotherapy are the most common course of treatment for B-cell lymphoma. Doxorubicin (DOX), gemcitabine (GEM), and vincristine (VCR) are the commonly used antilymphoma chemotherapeutic drugs. The aim of this study is to construct a novel drug delivery system for the combination delivery of the three drugs on lymphoma. Materials and methods DOX–GEM prodrug was synthesized. Novel nanostructured lipid carriers (NLCs) containing DOX–GEM prodrug and VCR were prepared and used to treat B-cell lymphoma through in vivo treatment to a lymph cancer animal model. The systemic toxicity of the nanomedicine was also evaluated during the treatment. Results DOX–GEM prodrug and VCR-loaded NLCs (DOX–GEM VCR NLCs) exhibited the highest antitumor effect in B-cell lymphoma cells and lymphoma animal xenografts when compared with the single drug-loaded NLCs and the drug solutions. Conclusion It could be concluded that the highest antitumor effect can be achieved by the system due to the stable drug-loading capacity, attractive anticancer therapeutic effects, and reduced toxicities in human Burkitt’s lymphoma cell line and mice-bearing cancer model. The resulting DOX–GEM VCR NLCs could be an efficient antilymph cancer agent and could be developed further for the treatment of other tumors.

show abstract

“…1 In other countries, the drug has also been approved for treatment of advanced breast cancer. 1,2 Moreover, evidence exists to support the use of vinorelbine in the management of a wide spectrum of cancers in humans, including cervical cancer, 8 ovarian cancer, 9 head and neck cancers, 10 esophageal squamous cell carcinoma, 11 mesothelioma, 12 multiple myeloma, 13 Hodgkin and non-Hodgkin lymphoma, 14,15 and pediatric brain tumors. 16 Vinorelbine is considered particularly promising for advanced-stage cancers in humans treated previously with vinca alkaloids because complete cross-resistance has not been reported for either of the more commonly administered vinca alkaloids (ie, vincristine and vinblastine).…”

mentioning

confidence: 99%

Clinical effects of vinorelbine administration in the management of various malignant tumor types in dogs: 58 cases (1997–2012)

Wouda

Miller²,

Chon³

et al. 2015

javma

View full text Add to dashboard Cite

Objective To evaluate the effectiveness of vinorelbine in the management of various malignant tumor types in dogs. Design Retrospective case series. Animals 58 dogs with malignant tumors, including pulmonary carcinoma (n = 31), histiocytic sarcoma (9), mast cell tumor (5), lymphoma (4), melanoma (2), and 7 other tumor types (1 each). Procedures Medical records of dogs treated with vinorelbine from December 1997 to December 2012 were reviewed for data regarding signalment, clinical signs, physical examination findings, clinicopathologic test results, diagnostic imaging results, vinorelbine doses and dose frequency, surgery and radiotherapy details when applicable, other chemotherapeutics administered, and outcomes. Descriptive, comparative, and survival statistics were computed for all dogs and for dogs by histologic subgroup of tumors. Results Vinorelbine was administered palliatively to 44 (76%) dogs. One (2%) dog had a complete response for 162 days, 5 (11%) dogs had a partial response for a median duration of 91 days, 19 (43%) dogs had stable disease for a median duration of 68 days, and 19 (43%) dogs developed progressive disease after a median duration of 21 days. Clinical benefit was more difficult to assess in the remaining 14 (24%) dogs that received vinorelbine as an adjuvant treatment. Overall median time to tumor progression was 103 days (range, 5 to 1,533 days). Conclusions and Clinical Relevance Vinorelbine appeared to be effective in the treatment of several tumor types in dogs. Follow-up prospective studies of the clinical benefit of the drug in specific clinical scenarios will be necessary to support this conclusion.

show abstract

Gemcitabine and vinorelbine chemotherapy for refractory or relapsing aggressive non‐Hodgkin lymphoma

Cited by 4 publications

References 11 publications

Gemcitabine Plus Vinorelbine for Refractory or Relapsing Non-Hodgkin Lymphoma: Response Rate and Survival

Gemcitabine Plus Vinorelbine for Refractory or Relapsing Non-Hodgkin Lymphoma: Response Rate and Survival

Lymph cancer chemotherapy: delivery of doxorubicin-gemcitabine prodrug and vincristine by nanostructured lipid carriers

Clinical effects of vinorelbine administration in the management of various malignant tumor types in dogs: 58 cases (1997–2012)

Contact Info

Product

Resources

About